WallStSmart

Sherwin-Williams Co (SHW)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sherwin-Williams Co generates 44062% more annual revenue ($24.41B vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 11.0%. VMET trades at a lower P/E of 28.7x. VMET earns a higher WallStSmart Score of 60/100 (C+).

SHW

Buy

60

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 3.3Quality: 4.0
Piotroski: 4/9Altman Z: 1.54

VMET

Buy

60

out of 100

Grade: C+

Growth: 10.0Profit: 8.5Value: 5.3Quality: 7.5
Piotroski: 5/9Altman Z: 1.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SHWOvervalued (-11.6%)

Margin of Safety

-11.6%

Fair Value

$331.27

Current Price

$369.73

$38.46 premium

UndervaluedFair: $331.27Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SHW3 strengths · Avg: 9.0/10
Return on EquityProfitability
69.7%10/10

Every $100 of equity generates 70 in profit

Market CapQuality
$87.77B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.24B8/10

Generating 1.2B in free cash flow

VMET6 strengths · Avg: 9.5/10
Profit MarginProfitability
58.4%10/10

Keeps 58 of every $100 in revenue as profit

Operating MarginProfitability
90.6%10/10

Strong operational efficiency at 90.6%

Revenue GrowthGrowth
594.0%10/10

Revenue surging 594.0% year-over-year

EPS GrowthGrowth
573.0%10/10

Earnings expanding 573.0% YoY

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Areas to Watch

SHW4 concerns · Avg: 3.0/10
P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.544/10

Distress zone — elevated risk

PEG RatioValuation
2.542/10

Expensive relative to growth rate

Price/BookValuation
23.2x2/10

Trading at 23.2x book value

VMET3 concerns · Avg: 3.0/10
P/E RatioValuation
28.7x4/10

Moderate valuation

Market CapQuality
$933.87M3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : SHW

The strongest argument for SHW centers on Return on Equity, Market Cap, Free Cash Flow.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.

Bear Case : SHW

The primary concerns for SHW are P/E Ratio, Altman Z-Score, PEG Ratio. Debt-to-equity of 3.69 is elevated, increasing financial risk.

Bear Case : VMET

The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.

Key Dynamics to Monitor

SHW profiles as a value stock while VMET is a growth play — different risk/reward profiles.

VMET is growing revenue faster at 594.0% — sustainability is the question.

SHW generates stronger free cash flow (1.2B), providing more financial flexibility.

Monitor SPECIALTY CHEMICALS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SHW scores higher overall (60/100 vs 60/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Sherwin-Williams Co

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

Sherwin Williams Company is a Cleveland, Ohio based company in the paint and coating manufacturing industry. The company primarily engages in the manufacture, distribution, and sale of paints, coatings, floorcoverings, and related products to professional, industrial, commercial, and retail customers primarily in North and South America and Europe.

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.

Want to dig deeper into these stocks?